(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

TERAPIA COMBINADA DE INIBIDOR de PI3K E INIBIDOR de PD-1

ArquivadaInvention PatentPCT · US2023014114

Application data

Invention Patent TERAPIA COMBINADA DE INIBIDOR de PI3K E INIBIDOR de PD-1 de MEI PHARMA, INC. — IPC A61K 31/53
Invention Patent TERAPIA COMBINADA DE INIBIDOR de PI3K E INIBIDOR de PD-1 de MEI PHARMA, INC. — IPC A61K 31/53. Drawing published by the INPI in the Industrial Property Gazette.

Number

112024017829

Type

Invention Patent

Filing

02/28/2023

Publication

12/17/2024

PCT

US2023014114

Progress at the INPI

  1. Filing02/28/23
  2. Publication12/17/24
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 02/28/2023 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 05/26/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

MEI PHARMA, INC.

US

See this company's full portfolio

Inventors

D. G. (pessoa física)

US

R. G. (pessoa física)

US

Technical data

Priority claims

US

63/315,380 · 03/01/2022

Abstract

TERAPIA COMBINADA DE INIBIDOR de PI3K E INIBIDOR de PD-1. São fornecidos aqui métodos de tratamento de doenças ou distúrbios proliferativos (por exemplo, um câncer) em um paciente que deles necessita usando uma terapia combinada do Composto (I) ou um sal farmaceuticamente aceitável do mesmo e um inibidor de PD-1 (por exemplo, Pembrolizumab).

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

05/26/2026

RPI 2890

Arquivamento - Art. 33 da LPI

#11.1

03/10/2026

RPI 2879

Notificação de entrada na fase nacional - PCT

#1.3

12/17/2024

RPI 2815

Alteração de dados cadastrais

#1.1

09/10/2024

RPI 2801

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.